» Articles » PMID: 35040730

Preparation of Topical Bimatoprost with Enhanced Skin Infiltration and Hair Regrowth Efficacy in Androgenic Alopecia

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2022 Jan 18
PMID 35040730
Authors
Affiliations
Soon will be listed here.
Abstract

To prepare a topical formulation of bimatoprost (BIM) with high skin permeability, we designed a solvent mixture system composed of ethanol, diethylene glycol monoethyl ether, cyclomethicone, and butylated hydroxyanisole, serving as a volatile solvent, nonvolatile co-solvent, spreading agent, and antioxidant, respectively. The ideal topical BIM formulation (BIM-TF#5) exhibited 4.60-fold higher human skin flux and a 529% increase in dermal drug deposition compared to BIM in ethanol. In addition, compared to the other formulations, BIM-TF#5 maximally activated human dermal papilla cell proliferation at a concentration of 5 μM BIM, equivalent to 10 μM minoxidil. Moreover, BIM-TF#5 (0.3% [w/w] BIM) significantly promoted hair regrowth in the androgenic alopecia mouse model and increased the area covered by hair at 10 days by 585% compared to the vehicle-treated mice, indicating that entire telogen area transitioned into the anagen phase. Furthermore, at day 14, the hair weight of mice treated with BIM-TF#5 (5% [w/w] BIM) was 8.45- and 1.30-fold greater than in the 5% (w/w) BIM in ethanol and 5% (w/v) minoxidil treated groups, respectively. In the histological examination, the number and diameter of hair follicles in the deep subcutis were significantly increased in the BIM-TF#5 (0.3 or 5% [w/w] BIM)-treated mice compared to the mice treated with vehicle or 5% (w/w) BIM in ethanol. Thus, our findings suggest that BIM-TF#5 is an effective formulation to treat scalp alopecia, as part of a novel therapeutic approach involving direct prostamide F2α receptor-mediated stimulation of dermal papilla cells within hair follicles.

Citing Articles

Understanding Microemulsions and Nanoemulsions in (Trans)Dermal Delivery.

Musakhanian J, Osborne D AAPS PharmSciTech. 2025; 26(1):31.

PMID: 39794642 DOI: 10.1208/s12249-024-02997-2.


Skin Penetration and Permeation Properties of Transcutol in Complex Formulations.

Musakhanian J, Osborne D, Rodier J AAPS PharmSciTech. 2024; 25(7):201.

PMID: 39235493 DOI: 10.1208/s12249-024-02886-8.


From Eye Care to Hair Growth: Bimatoprost.

Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794131 PMC: 11124470. DOI: 10.3390/ph17050561.


Spanlastic-laden nanogel as a plausible platform for dermal delivery of bimatoprost with superior cutaneous deposition and hair regrowth efficiency in androgenic alopecia.

Almutairy B, Khafagy E, Aldawsari M, Alshetaili A, Alotaibi H, Lila A Int J Pharm X. 2024; 7:100240.

PMID: 38577618 PMC: 10992714. DOI: 10.1016/j.ijpx.2024.100240.


Non-invasive assessment of hair regeneration in androgenetic alopecia mice using two-photon and second harmonic generation imaging.

He G, Liu M, Wang F, Sun S, Cao Y, Sun Y Biomed Opt Express. 2023; 14(11):5870-5885.

PMID: 38021124 PMC: 10659803. DOI: 10.1364/BOE.503312.


References
1.
Mura P, Faucci M, BRAMANTI G, Corti P . Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci. 2000; 9(4):365-72. DOI: 10.1016/s0928-0987(99)00075-5. View

2.
Ritschel W, Panchagnula R, Stemmer K, Ashraf M . Development of an intracutaneous depot for drugs. Binding, drug accumulation and retention studies, and mechanism of depot. Skin Pharmacol. 1991; 4(4):235-45. View

3.
Suchonwanit P, Thammarucha S, Leerunyakul K . Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019; 13:2777-2786. PMC: 6691938. DOI: 10.2147/DDDT.S214907. View

4.
Bjorklund S, Pham Q, Jensen L, Knudsen N, Nielsen L, Ekelund K . The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016; 479:207-220. DOI: 10.1016/j.jcis.2016.06.054. View

5.
Sallout B, Al Wadi K . Aphalangia possibly linked to unintended use of finasteride during early pregnancy. Ann Saudi Med. 2009; 29(2):155-6. PMC: 2813641. DOI: 10.4103/0256-4947.51805. View